UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 573

Sortiert nach

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Nature (London), 2022-03, Vol.603 (7903), p.942-948

2022

Volltextzugriff (PDF)

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Journal of thoracic oncology, 2022-02, Vol.17 (2), p.289-308

2022

Volltextzugriff (PDF)

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Journal of clinical oncology, 2021-04, Vol.39 (12), p.1349-1359

2021

Volltextzugriff (PDF)

Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer

Gynecologic oncology, 2020-10, Vol.159 (1), p.142-149

2020

Volltextzugriff (PDF)

Retrospective Evaluation of the Efficacy of Total Neoadjuvant Therapy and Chemoradiotherapy Neoadjuvant Treatment in Relation to Surgery in Patients with Rectal Cancer

Medicina (Kaunas, Lithuania), 2024-04, Vol.60 (4), p.656

2024

Volltextzugriff (PDF)

Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial

Nature communications, 2023-11, Vol.14 (1), p.7301-7301, Article 7301

2023

Volltextzugriff (PDF)

Depression and Anxiety - Risk Factors in the Evolution of Breast Cancer in Women

Brain. Broad research in artificial intelligence and neuroscience, 2022-06, Vol.13 (1Sup1), p.135-158

2022

Volltextzugriff (PDF)

Assessment of Epinephrine and Norepinephrine in Gastric Carcinoma

International journal of molecular sciences, 2021-02, Vol.22 (4), p.2042

2021

Volltextzugriff (PDF)

First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC)

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.391-391

2021

Volltextzugriff (PDF)

Current Trends in Cancer Management

2019

Volltextzugriff (PDF)

A case of metastatic non‐neural granular cell tumor in a 13‐year‐old girl

Journal of cutaneous pathology, 2014-06, Vol.41 (6), p.536-538

2014

Volltextzugriff (PDF)

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9501-9501

2020

Volltextzugriff (PDF)

Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9500-9500

2020

Volltextzugriff (PDF)

A Preliminary Study Examining the Correlation between EGFRI Treatment, Clinic Dermatoscopy Features, and Serum Levels of Anti-Alpha-Galactosyl IgE in Colorectal Cancer Patients

Gastroenterology insights, 2024-06, Vol.15 (2), p.505-518

2024

Volltextzugriff (PDF)

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

Journal for immunotherapy of cancer, 2024-02, Vol.12 (2), p.e008189

2024

Volltextzugriff (PDF)

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

Journal for immunotherapy of cancer, 2021-08, Vol.9 (8), p.e003188

2021

Volltextzugriff (PDF)

Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers—Early Experiences from Romania and Literature Review

Diagnostics (Basel), 2023-08, Vol.13 (16), p.2620

2023

Volltextzugriff (PDF)

The Prognostic Correlation of Heart Rate Variability at Diagnosis with Survival of Patients with Hepatocellular Carcinoma

Diagnostics (Basel), 2021-05, Vol.11 (5), p.890

2021

Volltextzugriff (PDF)

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

The New England journal of medicine, 2017-11, Vol.377 (19), p.1824-1835

2017

Volltextzugriff (PDF)

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

The New England journal of medicine, 2021-06, Vol.384 (22), p.2102-2114

2021

Volltextzugriff (PDF)

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

The New England journal of medicine, 2021-04, Vol.384 (13), p.1191-1203

2021

Volltextzugriff (PDF)

1 – 25 von 573

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(273)
Mit Volltextzugriff
(531)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer

Retrospective Evaluation of the Efficacy of Total Neoadjuvant Therapy and Chemoradiotherapy Neoadjuvant Treatment in Relation to Surgery in Patients with Rectal Cancer

Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial

Depression and Anxiety - Risk Factors in the Evolution of Breast Cancer in Women

Assessment of Epinephrine and Norepinephrine in Gastric Carcinoma

First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC)

Current Trends in Cancer Management

A case of metastatic non‐neural granular cell tumor in a 13‐year‐old girl

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA

Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1

A Preliminary Study Examining the Correlation between EGFRI Treatment, Clinic Dermatoscopy Features, and Serum Levels of Anti-Alpha-Galactosyl IgE in Colorectal Cancer Patients

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers—Early Experiences from Romania and Literature Review

The Prognostic Correlation of Heart Rate Variability at Diagnosis with Survival of Patients with Hepatocellular Carcinoma

Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Suchergebnisse filtern